Oryzon Genomics widens losses to 1.7 million in the first quarter

Biopharmaceutical company Oryzon's net loss in the first quarter of the year widened to €1.7 million, compared to €1.1 million a year earlier. The company says this result is in line with its business model, which focuses on long-term product development.